All In Biotech

Drug Trial Radar · NCT07115043

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 29, 2025

Primary completion

Oct 2, 2029

Study completion Oct 2, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Conditions

  • Melanoma
  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma (Skin)
  • Renal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Triple Negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Gastric Cancer/Gastroesophageal Junction Cancer
  • High Grade Serous Ovarian Carcinoma

Interventions

  • AZD6750Drug

    AZD6750- CD8 guided IL-2

  • rilvegostomigDrug

    Rilvegostomig- PD1-TIGIT bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)Time frame: Measured from the informed consent until Day 90 post-last dose.
  2. Efficacy- Part 2B only (dose expansion)Time frame: Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years)

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    East Melbourne, Australia · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.